Market Place
Sourcing Support
RedHill`s Opaganib Gets FDA Orphan Drug Status For Childhood Neuroblastoma
26 Aug 2024 //
PR NEWSWIRE
RedHill Announces Positive Obesity and Diabetes Results with Opaganib
19 Aug 2024 //
PR NEWSWIRE
RedHill Patents Opaganib Combo With Checkpoint Inhibitors Through 2040
03 Jun 2024 //
PR NEWSWIRE
RedHill obtains Chinese patent for Opaganib against Ebola
06 May 2024 //
PR NEWSWIRE
RedHill`s Opaganib Selected for Evaluation by BARDA
05 Mar 2024 //
PR NEWSWIRE
RedHill`s Opaganib Protects Against Radiation-Induced Lung Inflammation
20 Feb 2024 //
PR NEWSWIRE
RedHill Announces New USPTO Notice of Patent Allowance for Opaganib
05 Sep 2023 //
PR NEWSWIRE
RedHill`s RHB-102 (BEKINDA®) & Opaganib Granted New Patents in Oncology Setting
01 May 2023 //
PR NEWSWIRE
RedHill`s Opaganib Selected by the NIH Radiation and Countermeasures Program
28 Feb 2023 //
PR NEWSWIRE
RedHill`s Opaganib and RHB-107, Inhibit Dominant Omicron Sub-Variant BA.5
04 Oct 2022 //
PRESS RELEASE
RedHill Reports Potent Inhibition of Omicron with Opaganib In Vitro
11 Apr 2022 //
PRNEWSWIRE
RedHill Biopharma`s Oral Opaganib Reduces Mortality by 70%
07 Feb 2022 //
PRNEWSWIRE
RedHill`s Opaganib Significantly Improves Viral Clearance in Phase 2/3 Study
13 Jan 2022 //
PRNEWSWIRE
Opaganib reduces COVID-19 mortality by 62 percent in Phase II/III study
07 Oct 2021 //
EUROPEANPHARMACEUTICALREVIEW
RedHill reports data from Covid-19 clinical trial of opaganib
05 Oct 2021 //
CLINICALTRIALSARENA
RedHill Reports Top-Line Opaganib Data from PII/III Study in COVID-19 Patients
14 Sep 2021 //
PRNEWSWIRE
RedHill Biopharma`s Opaganib Shows Significant Reduction in Kidney Fibrosis
08 Sep 2021 //
PRNEWSWIRE
RedHill Biopharma`s Opaganib Shows Significant Decrease in Kidney Fibrosis
07 Sep 2021 //
PRNEWSWIRE
RedHill Biopharma`s opaganib inhibits COVID-19 variants in a preclinical study
30 Jun 2021 //
PR NEWSWIRE
RedHill Biopharma`s drug candidate opaganib inhibits COVID-19 variants
29 Jun 2021 //
PR NEWSWIRE
RedHill Biopharma`s Opaganib Inhibits COVID-19 Variants in Preclinical Study
28 Jun 2021 //
PR NEWSWIRE
RedHill Announces Presentation of Positive Phase 2 Data for Opaganib
23 Jun 2021 //
PRNEWSWIRE
RedHill Biopharma Announces Oral Opaganib Phase 2 Positive Data Submission
22 Jun 2021 //
PRNEWSWIRE
RedHill Announces of Positive Oral Opaganib Phase 2 Data in COVID-19
21 Jun 2021 //
PRNEWSWIRE
RedHill Biopharma Ramps-Up Manufacturing of Opaganib
15 Oct 2020 //
CONTRACTPHARMA
RedHill Biopharma Announces Partnerships to Expand Manufacturing Opaganib
13 Oct 2020 //
GLOBENEWSWIRE
Mid-stage study of RedHill Biopharma`s opaganib in COVID-19
07 Oct 2020 //
SEEKING ALPHA
Brazil Approves RedHill Biopharma’s Phase 2/3 COVID-19 Study with Opaganib
22 Sep 2020 //
GLOBENEWSWIRE
RedHill Biopharma’s Opaganib Demonstrates Complete Inhibition of SARS-CoV-2
08 Sep 2020 //
PRESS RELEASE
RedHill Biopharma’s Phase 2/3 COVID-19 Study Approved in Mexico
06 Aug 2020 //
GLOBENEWSWIRE
RedHill Biopharma Initiates Global Phase 2/3 Study for COVID-19
30 Jul 2020 //
GLOBENEWSWIRE
RedHill Biopharma Receives Approval for COVID-19 Phase 2/3 Study with Opaganib
29 Jun 2020 //
GLOBENEWSWIRE
RedHill Biopharma Submits COVID-19 Trial for PH 2/3 Study with Opaganib
10 Jun 2020 //
GLOBENEWSWIRE
BRIEF-Six Covid-19 Patients Treated With Redhill’S Opaganib Compassionate Use
27 Apr 2020 //
REUTERS
IND for COVID-19 with Opaganib Submitted to the FDA by RedHill Biopharma
17 Apr 2020 //
GLOBENEWSWIRE
Initial data shows improvement in Covid-19 with RedHill’s opaganib
14 Apr 2020 //
CLINICALTRIALSARENA
Initial data shows improvement in Covid-19 with RedHill’s opaganib
13 Apr 2020 //
CLINICALTRIALSARENA
